This company has been marked as potentially delisted and may not be actively trading. Miragen Therapeutics (MGEN) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock MGEN vs. XGN, SERA, MDXH, BDSX, OPGN, BNR, ENZ, BGLC, ACON, and NTRAShould you be buying Miragen Therapeutics stock or one of its competitors? The main competitors of Miragen Therapeutics include Exagen (XGN), Sera Prognostics (SERA), MDxHealth (MDXH), Biodesix (BDSX), OpGen (OPGN), Burning Rock Biotech (BNR), Enzo Biochem (ENZ), BioNexus Gene Lab (BGLC), Aclarion (ACON), and Natera (NTRA). Miragen Therapeutics vs. Exagen Sera Prognostics MDxHealth Biodesix OpGen Burning Rock Biotech Enzo Biochem BioNexus Gene Lab Aclarion Natera Miragen Therapeutics (NASDAQ:MGEN) and Exagen (NASDAQ:XGN) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, institutional ownership, risk, dividends, earnings, profitability and community ranking. Which has preferable earnings & valuation, MGEN or XGN? Exagen has higher revenue and earnings than Miragen Therapeutics. Exagen is trading at a lower price-to-earnings ratio than Miragen Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMiragen Therapeutics$4.46M11.87-$41.87M-$20.09-0.67Exagen$55.64M1.99-$23.69M-$0.83-7.46 Which has more risk & volatility, MGEN or XGN? Miragen Therapeutics has a beta of 1.66, meaning that its stock price is 66% more volatile than the S&P 500. Comparatively, Exagen has a beta of 1.46, meaning that its stock price is 46% more volatile than the S&P 500. Is MGEN or XGN more profitable? Exagen has a net margin of -30.36% compared to Miragen Therapeutics' net margin of -1,393.50%. Exagen's return on equity of -92.58% beat Miragen Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Miragen Therapeutics-1,393.50% -141.66% -88.74% Exagen -30.36%-92.58%-33.74% Do analysts rate MGEN or XGN? Exagen has a consensus target price of $7.50, suggesting a potential upside of 21.07%. Given Exagen's stronger consensus rating and higher probable upside, analysts clearly believe Exagen is more favorable than Miragen Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Miragen Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Exagen 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community favor MGEN or XGN? Miragen Therapeutics received 243 more outperform votes than Exagen when rated by MarketBeat users. Likewise, 70.45% of users gave Miragen Therapeutics an outperform vote while only 58.54% of users gave Exagen an outperform vote. CompanyUnderperformOutperformMiragen TherapeuticsOutperform Votes26770.45% Underperform Votes11229.55% ExagenOutperform Votes2458.54% Underperform Votes1741.46% Does the media favor MGEN or XGN? In the previous week, Exagen had 4 more articles in the media than Miragen Therapeutics. MarketBeat recorded 4 mentions for Exagen and 0 mentions for Miragen Therapeutics. Exagen's average media sentiment score of 1.06 beat Miragen Therapeutics' score of 0.00 indicating that Exagen is being referred to more favorably in the news media. Company Overall Sentiment Miragen Therapeutics Neutral Exagen Positive Do insiders and institutionals hold more shares of MGEN or XGN? 75.3% of Exagen shares are owned by institutional investors. 1.1% of Miragen Therapeutics shares are owned by company insiders. Comparatively, 26.1% of Exagen shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. SummaryExagen beats Miragen Therapeutics on 13 of the 18 factors compared between the two stocks. Get Miragen Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MGEN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MGEN vs. The Competition Export to ExcelMetricMiragen TherapeuticsMedical Laboratories IndustryMedical SectorNASDAQ ExchangeMarket Cap$52.95M$2.91B$5.53B$7.99BDividend YieldN/A31.29%5.11%4.23%P/E Ratio-1.2713.3322.6518.64Price / Sales11.87188.97401.98103.80Price / CashN/A57.5638.1834.62Price / Book2.004.786.754.30Net Income-$41.87M-$22.21M$3.22B$248.44M Miragen Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MGENMiragen TherapeuticsN/A$13.55+2.8%N/A-0.6%$52.95M$4.46M-1.2745High Trading VolumeXGNExagen4.0715 of 5 stars$6.58-1.1%$7.50+14.0%+354.7%$117.05M$55.64M-6.96220Positive NewsSERASera Prognostics1.1307 of 5 stars$3.00-0.2%N/A-74.9%$112.80M$77,000.00-3.03120Short Interest ↓MDXHMDxHealth2.8783 of 5 stars$1.85+2.5%$6.50+252.3%-30.8%$87.25M$90.05M-1.21300Upcoming EarningsShort Interest ↓News CoverageBDSXBiodesix3.3022 of 5 stars$0.56-1.5%$2.86+407.1%-56.9%$83.62M$71.32M-1.46220Analyst ForecastNews CoverageOPGNOpGenN/A$4.99+0.4%N/A+23.6%$41.70M$2.67M0.00100Gap DownBNRBurning Rock Biotech1.8624 of 5 stars$2.86+0.7%N/A-61.3%$29.30M$515.82M-0.951,390Short Interest ↓Positive NewsGap UpENZEnzo Biochem0.5475 of 5 stars$0.33-14.8%N/A-69.0%$17.03M$29.09M0.00520Gap DownHigh Trading VolumeBGLCBioNexus Gene Lab0.2733 of 5 stars$2.83+4.4%N/A-54.0%$5.03M$9.51M0.0030Short Interest ↑News CoverageGap DownACONAclarion1.5166 of 5 stars$6.82-0.4%$11,758.50+172,312.0%-99.8%$3.98M$45,724.000.007Positive NewsGap DownNTRANatera2.8621 of 5 stars$154.01+0.7%$175.76+14.1%+62.5%$20.78B$1.70B-87.343,020Upcoming EarningsInsider TradePositive News Related Companies and Tools Related Companies Exagen Alternatives Sera Prognostics Alternatives MDxHealth Alternatives Biodesix Alternatives OpGen Alternatives Burning Rock Biotech Alternatives Enzo Biochem Alternatives BioNexus Gene Lab Alternatives Aclarion Alternatives Natera Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MGEN) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | SponsoredThey rigged the gameThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Miragen Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Miragen Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy MGEN Stock Free MGEN Stock Alerts